Brief: Cymabay's Seladelpar Achieves High Statistical Significance In The Phase 3 Response Trial

CymaBay Therapeutics

07/09/2023 13:23

Sept 7 (Reuters) - Cymabay Therapeutics Inc  CBAY.O :
    * CYMABAY'S SELADELPAR ACHIEVES HIGH STATISTICAL
SIGNIFICANCE FOR
THE PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 RESPONSE
TRIAL IN PRIMARY BILIARY CHOLANGITIS
    * CYMABAY THERAPEUTICS INC: REGISTRATION TRIAL ACHIEVED
PRIMARY
AND ALL KEY SECONDARY ENDPOINTS
    * CYMABAY THERAPEUTICS INC: SAFETY WAS COMPARABLE BETWEEN
PLACEBO
AND SELADELPAR GROUPS AND WAS CONSISTENT WITH PREVIOUS STUDIES

Source text for Eikon:  ID:nPn1ffkY0a 
Further company coverage:  CBAY.O 

 ((Reuters.Briefs@thomsonreuters.com;))